

Sang Taek Jung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1061485/publications.pdf>

Version: 2024-02-01

32
papers

797
citations

758635

12
h-index

525886

27
g-index

34
all docs

34
docs citations

34
times ranked

996
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes. <i>Nature Communications</i> , 2022, 13, 2127.	5.8	7
2	Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering. <i>BioDrugs</i> , 2021, 35, 147-157.	2.2	24
3	Improved Yield of Recombinant Protein via Flagella Regulator Deletion in <i>Escherichia coli</i> . <i>Frontiers in Microbiology</i> , 2021, 12, 655072.	1.5	4
4	A human antibody against human endothelin receptor type A that exhibits antitumor potency. <i>Experimental and Molecular Medicine</i> , 2021, 53, 1437-1448.	3.2	12
5	The role of oxytocin, vasopressin, and their receptors at nociceptors in peripheral pain modulation. <i>Frontiers in Neuroendocrinology</i> , 2021, 63, 100942.	2.5	9
6	Structural Study on the Impact of S239D/I332E Mutations in the Binding of Fc and Fc γ R1IIa. <i>Biotechnology and Bioprocess Engineering</i> , 2021, 26, 985-992.	1.4	3
7	Computer-based engineering of thermostabilized antibody fragments. <i>AIChE Journal</i> , 2020, 66, e16864.	1.8	12
8	Assessment of Computational Modeling of Fc-Fc Receptor Binding Through Protein-protein Docking Tool. <i>Biotechnology and Bioprocess Engineering</i> , 2020, 25, 734-741.	1.4	11
9	Antigen Design for Successful Isolation of Highly Challenging Therapeutic Anti-GPCR Antibodies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8240.	1.8	9
10	Engineered human Fc γ R1IIa fusion: A novel strategy to extend serum half-life of therapeutic proteins. <i>Biotechnology and Bioengineering</i> , 2020, 117, 2351-2361.	1.7	2
11	Discovery of Novel <i>Pseudomonas putida</i> Flavin-Binding Fluorescent Protein Variants with Significantly Improved Quantum Yield. <i>Journal of Agricultural and Food Chemistry</i> , 2020, 68, 5873-5879.	2.4	11
12	Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer. <i>Biomolecules</i> , 2020, 10, 382.	1.8	8
13	Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies. <i>Molecular Immunology</i> , 2019, 114, 62-71.	1.0	5
14	Construction of an immunotoxin via site-specific conjugation of anti-Her2 IgG and engineered <i>Pseudomonas</i> exotoxin A. <i>Journal of Biological Engineering</i> , 2019, 13, 56.	2.0	12
15	Engineered <i>Arabidopsis</i> Blue Light Receptor LOV Domain Variants with Improved Quantum Yield, Brightness, and Thermostability. <i>Journal of Agricultural and Food Chemistry</i> , 2019, 67, 12037-12043.	2.4	12
16	Isolation of Single Chain Antibodies Specific to Lysophosphatidic Acid Receptor 1 (LPA 1) from a M13 Phage Display Library Using Purified LPA 1 Stabilized in Nanodiscs. <i>Bulletin of the Korean Chemical Society</i> , 2019, 40, 680-685.	1.0	0
17	Boosting therapeutic potency of antibodies by taming Fc domain functions. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-9.	3.2	77
18	Detection and purification of backbone-cyclized proteins using a bacterially expressed anti-myc-tag single chain antibody. <i>Analytical Biochemistry</i> , 2017, 532, 38-44.	1.1	0

#	ARTICLE	IF	CITATIONS
19	Determination of the endothelin-1 recognition sites of endothelin receptor type A by the directed-degeneration method. <i>Scientific Reports</i> , 2017, 7, 7577.	1.6	3
20	The Highly Evolvable Antibody Fc Domain. <i>Trends in Biotechnology</i> , 2016, 34, 895-908.	4.9	39
21	Engineering therapeutic antibodies targeting G-protein-coupled receptors. <i>Experimental and Molecular Medicine</i> , 2016, 48, e207-e207.	3.2	82
22	Structural consequences of aglycosylated IgG Fc variants evolved for Fc γ RI binding. <i>Molecular Immunology</i> , 2015, 67, 350-356.	1.0	15
23	Engineering antibodies for dual specificity and enhanced potency. <i>Biotechnology and Bioprocess Engineering</i> , 2015, 20, 201-210.	1.4	4
24	Engineering an aglycosylated Fc variant for enhanced Fc γ RI engagement and pH-dependent human FcRn binding. <i>Biotechnology and Bioprocess Engineering</i> , 2014, 19, 780-789.	1.4	11
25	Aglycosylated full-length IgG antibodies: steps toward next-generation immunotherapeutics. <i>Current Opinion in Biotechnology</i> , 2014, 30, 128-139.	3.3	50
26	Tailoring immunoglobulin Fc for highly potent and serum-stable therapeutic antibodies. <i>Biotechnology and Bioprocess Engineering</i> , 2013, 18, 625-636.	1.4	11
27	Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High Fc γ RIIIa Affinity and Selectivity. <i>ACS Chemical Biology</i> , 2013, 8, 368-375.	1.6	61
28	Recent development of highly sensitive protease assay methods: Signal amplification through enzyme cascades. <i>Biotechnology and Bioprocess Engineering</i> , 2012, 17, 1113-1119.	1.4	19
29	Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy. <i>Current Opinion in Biotechnology</i> , 2011, 22, 858-867.	3.3	88
30	Efficient expression and purification of human aglycosylated Fc γ RI β receptors in <i>Escherichia coli</i> . <i>Biotechnology and Bioengineering</i> , 2010, 107, 21-30.	1.7	15
31	Aglycosylated IgG variants expressed in bacteria that selectively bind Fc γ RI potentiate tumor cell killing by monocyte-dendritic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 604-609.	3.3	146
32	Binding and enrichment of <i>Escherichia coli</i> spheroplasts expressing inner membrane tethered scFv antibodies on surface immobilized antigens. <i>Biotechnology and Bioengineering</i> , 2007, 98, 39-47.	1.7	34